NCT03175549View on ClinicalTrials.gov

Medication Development in Alcoholism: Apremilast Versus Placebo

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

November 1, 2017

Primary Completion Date

April 1, 2020

Study Completion Date

April 1, 2020

Conditions
Alcohol Use Disorder
Interventions
DRUG

Apremilast

Fixed oral dose of 90 mg/d following the standard titration for a total dosing duration of 14 days.

DRUG

Placebo

Identical placebo pills taken orally for 14 days

Trial Locations (1)

92037

The Scripps Research Institute Pearson Center for Alcoholism and Addiction Research, La Jolla

All Listed Sponsors
collaborator

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

lead

The Scripps Research Institute

OTHER

NCT03175549 - Medication Development in Alcoholism: Apremilast Versus Placebo | Biotech Hunter | Biotech Hunter